title: Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
authors.forename: Walter M
authors.initials: WM
authors.lastname: Stadler
authors.forename: Laura C
authors.initials: LC
authors.lastname: Michaelis
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Ratain
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000175:diagnosis / Q000188:drug therapy*; D017430:Prostate-Specific Antigen / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen